- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 17, Issue 19, 2011
Current Pharmaceutical Design - Volume 17, Issue 19, 2011
Volume 17, Issue 19, 2011
-
-
Editorial [Hot topic: The Urokinase Receptor System as Strategic Therapeutic Target: Challenges for the 21st Century (Executive Guest Editor: Bernard Degryse)]
More LessThe story that led to the discovery of urokinase receptor (uPAR) system started in 1947 with the report of MacFarlane and Pilling who identified but did not named urokinase (uPA). Today, the uPAR system is recognized as one very important actor in tumourigenesis and is even considered as a valuable tumour marker. Its critical functions justify the important effort of translational research that has produced many inhibitors whi Read More
-
-
-
The Urokinase Receptor Interactome
Authors: Gabriele Eden, Marco Archinti, Federico Furlan, Ronan Murphy and Bernard DegryseThe urokinase receptor (uPAR) was originally identified as the membrane receptor of the serine protease urokinase (uPA), thereby implicated in the plasminogen activation cascade and regulation of pericellular proteolysis. Later on, vitronectin was showed to be another major ligand providing uPAR with a role in cell adhesion. Other unrelated ligands have been subsequently reported including for example factor XII and SRPX2 Read More
-
-
-
Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Since decades the urokinase plasminogen activator (uPA) system has been associated with the invasion of malignant cells. The receptor of urokinase (uPAR) is one of the key players in this proteolytic cascade, because it focuses uPA's proteolytic activity to the cell surface and in addition functions as a signaling receptor. uPAR is highly expressed in virtually all human cancers, suggesting possible clinical applications as diag Read More
-
-
-
The Urokinase Receptor in Hematopoietic Stem Cells Mobilization
More LessThe receptor for urokinase plasminogen activator (uPAR) is required in hematopoietic stem/progenitor cells (HSC, HPC) mobilization in the mouse. Indeed, uPAR Ko mice are deficient both in retention and mobilization of HSC and HPC, because uPAR causes their retention in the BM through its interaction with the α4β1 integrin and at the same time its removal promotes their migration. Normally, the membrane signal is cleaved Read More
-
-
-
The Role of the Urokinase Receptor in Epilepsy, in Disorders of Language, Cognition, Communication and Behavior, and in the Central Nervous System
Authors: Nadine Bruneau and Pierre SzepetowskiAs a key component of the plasminogen activation system, uPAR, the receptor for the plasminogen activator of the urokinase type, is involved in many physiological and pathological processes. Besides its classical roles, there has been increased evidence that uPAR or uPAR-associated pathways, participate in the development, in the functioning and in the pathology of the central nervous system. Qualitative and quantit Read More
-
-
-
The Urokinase Receptor System, A Key Regulator at the Intersection between Inflammation, Immunity, and Coagulation
The urokinase plasminogen activator (uPA) and its receptor (uPAR) provide a cell surface integrated multimolecular complex that exerts pleiotropic functions influencing the development of inflammatory, immune, coagulation and fibrinolytic responses. Here we review the evidences indicating a role of the uPA/uPAR system in the regulation of the innate immune system in the inflammation process, of the adaptive immune respon Read More
-
-
-
The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Authors: Maria Vincenza Carriero and Maria Patrizia StoppelliUrokinase (uPA) was originally identified in human urine for its ability to catalyse the transformation of plasminogen into its active form, plasmin which degrades fibrin and extracellular matrix components. Two major, functionally independent regions have been identified in the uPA molecule: a non-catalytic N-terminal region (residues 1-135) and a large catalytic region (residues 159-411) spaced by the “connecting peptide” (r Read More
-
-
-
Regulation of the Urokinase Receptor (uPAR) by LDL Receptor-related Protein-1 (LRP1)
Authors: Steven L. Gonias, Alban Gaultier and Minji JoLDL receptor-related protein (LRP1) is an endocytic receptor for multiple ligands, including proteases, growth factors, apolipoproteins, and extracellular matrix proteins. In some cell types, including neurons, neuron-like cells, and Schwann cells, ligand-binding to LRP1 triggers robust cell-signaling. This “direct” pathway by which LRP1 regulates cell-signaling promotes cell survival and cell migration. LRP1 also regulates the Read More
-
-
-
Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
Authors: Andrew P. Mazar, Richard W. Ahn and Thomas V. O'HalloranThe urokinase plasminogen activator receptor (uPAR) mediates cell motility and tissue remodeling. Although uPAR may be expressed transiently in many tissues during development and wound healing, its constitutive expression appears to be associated with several pathological conditions, including cancer. uPAR expression has been demonstrated in most solid tumors and several hematologic malignancies including multiple Read More
-
-
-
Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Authors: Maddalena de Virgilio and Franco SilvestrisThe urokinase receptor (uPAR) exerts essential functions in the pathophysiology of cancers and therefore constitutes an important drug target. In order to generate efficient drugs against uPAR, a new approach includes chimeric proteins associating one molecular address to specifically target uPAR and one bacterial or plant toxin that will eventually kill the tumoral cell. Using this frame, several recombinant toxins have been de Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 16 (2010)
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
